Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement

Dhrubajyoti Bandyopadhyay; Sandipan Chakraborty; Birendra Amgai; Samir R Kapadia; Eugene Braunwald; Srihari S Naidu; Ankur Kalra

doi:10.1001/jamanetworkopen.2019.21669

Association of Hypertrophic Obstructive Cardiomyopathy With Outcomes Following Transcatheter Aortic Valve Replacement

JAMA Netw Open. 2020 Feb 5;3(2):e1921669. doi: 10.1001/jamanetworkopen.2019.21669.

Authors

Dhrubajyoti Bandyopadhyay¹, Sandipan Chakraborty², Birendra Amgai², Samir R Kapadia³, Eugene Braunwald⁴, Srihari S Naidu⁵, Ankur Kalra³

Affiliations

¹ Icahn School of Medicine at Mount Sinai, St Luke's Roosevelt Hospital, New York, New York.
² Interfaith Medical Center, Brooklyn, New York.
³ Heart and Vascular Institute, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.
⁴ TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts.
⁵ Westchester Medical Center and New York Medical College, Valhalla, New York.

Abstract

This cohort study investigates the association of hypertrophic obstructive cardiomyopathy with outcomes following transcatheter aortic valve replacement.

MeSH terms

Aged
Aged, 80 and over
Aortic Valve Stenosis / complications*
Aortic Valve Stenosis / therapy
Cardiomyopathy, Hypertrophic / complications*
Cardiomyopathy, Hypertrophic / therapy
Female
Humans
Male
Middle Aged
Retrospective Studies
Transcatheter Aortic Valve Replacement / adverse effects*
Ventricular Outflow Obstruction / etiology
Ventricular Outflow Obstruction / therapy